RxDoctor Payments Data

Shana Krstevska, MD

Neurology · Troy, MINPI 1750456497

Payments from drug & device makers

$110,925in general payments, 2019–2025

Across 187 payments — averaging $593.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$55K
  • Acadia Pharmaceuticals Inc$21K
  • Janssen Research & Development, LLC$14K
  • UCB SA$11K
  • Abbott$4K
  • UCB, Inc.$2K
  • plus $5K from 15 others

What the payments were for

  • Consulting fees$3,63725%
  • Travel & lodging$4,69533%
  • Food & beverage$5,99442%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,925 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$79,668
Medicare patients
247
Services billed
846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$388,494
AustedoDeutetrabenazine19$183,486
GocovriAmantadine Hcl33$108,182
RytaryCarbidopa/Levodopa36$70,892
NourianzIstradefylline21$49,549
Carbidopa-LevodopaCarbidopa/Levodopa803$48,765
Tetrabenazine16$40,679
Pramipexole ErPramipexole Di-Hcl57$23,145
Rasagiline Mesylate118$22,337
Ropinirole ErRopinirole Hcl61$16,032
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone34$13,800
Selegiline Hcl45$9,918
AmantadineAmantadine Hcl121$8,213
Entacapone32$6,699
Pramipexole DihydrochloridePramipexole Di-Hcl200$6,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,129$388,49434 claims
Teva Pharmaceuticals USA, Inc.Austedo$135$183,48619 claims
MDD US Operations, LLCGocovri$377$108,18233 claims
Amneal Pharmaceuticals LLCRytary$255$70,89236 claims
Kyowa Kirin, Inc.Nourianz$203$49,54921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →